U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Sagimet Biosciences

Market Cap: US$74.4m

A clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States.

RenovoRx

Market Cap: US$28.2m

A clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.

HilleVax

Market Cap: US$82.2m

A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States.

Nurix Therapeutics

Market Cap: US$696.8m

A clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.

PharmaCyte Biotech

Market Cap: US$8.3m

A biotechnology company, develops and commercializes cellular therapies for cancer in the United States.

Vanda Pharmaceuticals

Market Cap: US$254.3m

A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.

ADMA Biologics

Market Cap: US$4.6b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Biogen

Market Cap: US$16.9b

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

Exelixis

Market Cap: US$9.9b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

Corcept Therapeutics

Market Cap: US$7.2b

Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

ACADIA Pharmaceuticals

Market Cap: US$2.4b

A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.

Intellia Therapeutics

Market Cap: US$767.1m

A clinical-stage gene editing company, focuses on the development of curative genome editing treatments.

Nkarta

Market Cap: US$111.8m

A clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.

Matinas BioPharma Holdings

Market Cap: US$2.7m

A clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology.

Azitra

Market Cap: US$4.4m

An early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases.

United Therapeutics

Market Cap: US$12.6b

A biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

Grace Therapeutics

Market Cap: US$27.2m

Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.

TransCode Therapeutics

Market Cap: US$9.4m

A biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer.

Entera Bio

Market Cap: US$76.8m

A clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care.

Beam Therapeutics

Market Cap: US$1.5b

A biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.

AC Immune

Market Cap: US$154.4m

A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.

IDEAYA Biosciences

Market Cap: US$1.5b

A precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.

Design Therapeutics

Market Cap: US$164.0m

A clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.

Kura Oncology

Market Cap: US$466.0m

A clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.

Dynavax Technologies

Market Cap: US$1.4b

A commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally.

Talphera

Market Cap: US$8.5m

A specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.

Caribou Biosciences

Market Cap: US$81.3m

A clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally.

MediWound

Market Cap: US$176.9m

A biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally.

HOOKIPA Pharma

Market Cap: US$9.5m

A clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform.

Climb Bio

Market Cap: US$86.4m

A clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases.

Structure Therapeutics

Market Cap: US$911.8m

A clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.

Viridian Therapeutics

Market Cap: US$979.4m

Engages in discovering, developing, and commercializing treatments for serious and rare diseases.

Sionna Therapeutics

Market Cap: US$347.3m

A clinical-stage biopharmaceutical company, develops medicines for the treatment of cystic fibrosis (CF).

Clearmind Medicine

Market Cap: US$4.9m

A clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems.

OnKure Therapeutics

Market Cap: US$39.6m

A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers.

C4 Therapeutics

Market Cap: US$88.0m

A clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.